Miyoshi Toru, Nishimura Takashi, Hiasa Yu, Izutani Hironori, Yamaguchi Osamu
Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine, Toon, JPN.
Department of Cardiovascular Surgery, Ehime University Graduate School of Medicine, Toon, JPN.
Cureus. 2024 Sep 28;16(9):e70399. doi: 10.7759/cureus.70399. eCollection 2024 Sep.
An Impella device (Abiomed, Inc., Danvers, Massachusetts, United States) is a useful percutaneous left ventricular assist device for patients with cardiogenic shock. However, there are cases in which patients are unable to escape cardiogenic shock and become Impella-dependent. Long-term management can lead to thrombus. A man in his thirties experienced acute myocardial infarction necessitating Impella 5.5 support. Initially, a thrombus was not detected in the ascending aorta. Nonetheless, a mobile thrombus was observed post-Impella removal. His computed tomography revealed thrombosis in the iliac artery the following day. Diligent monitoring during Impella removal is imperative.
Impella装置（美国马萨诸塞州丹弗斯市的Abiomed公司）是用于心源性休克患者的一种有用的经皮左心室辅助装置。然而，存在患者无法摆脱心源性休克并对Impella产生依赖的情况。长期管理可能会导致血栓形成。一名三十多岁的男性经历了急性心肌梗死，需要Impella 5.5支持。最初，升主动脉未检测到血栓。尽管如此，在移除Impella后观察到了一个活动血栓。第二天他的计算机断层扫描显示髂动脉有血栓形成。在移除Impella期间进行认真监测至关重要。
